<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996657</url>
  </required_header>
  <id_info>
    <org_study_id>2013-P-002</org_study_id>
    <nct_id>NCT01996657</nct_id>
  </id_info>
  <brief_title>D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement</brief_title>
  <acronym>3D-INTENSITY</acronym>
  <official_title>D-dimer Levels Determined the Intensity of Anticoagulation Therapy to Improve Outcomes in Patients With Mechanical Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal intensity of oral anticoagulation in China patients undergoing mechanical valve
      replacements is still controversial due to the different risk profiles of thrombophilia and
      bleeding in Chinese patients. Elevated D-dimer could reflect a pro-thrombogenic or
      prothrombotic state, and thus might be used to decide the intensity of oral anticoagulation.

      This study was to evaluate whether elevated D-dimer levels could help to determine the
      intensity of oral anticoagulation in patients with mechanical heart valve prostheses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The optimal intensity of oral anticoagulation in China patients undergoing
      mechanical valve replacements is still controversial due to the different risk profiles of
      thrombophilia and bleeding in Chinese patients. Elevated D-dimer could reflect a
      pro-thrombogenic or prothrombotic state, and thus might be used to decide the intensity of
      oral anticoagulation.

      Objective: This study was to evaluate whether elevated D-dimer levels could help to determine
      the intensity of oral anticoagulation in patients with mechanical heart valve prostheses.

      Methods: A single-center, prospective study was performed. 748 Patients with mechanical valve
      replacement who had received oral anticoagulation. The patients were randomly assigned to
      three groups The intensity of anticoagulation for group one was standard intensity
      (INR:2.5-3.5). The intensity of anticoagulation for group two was kept at low intensity
      without adjustment (INR:1.8-2.6), and for group three , The intensity of anticoagulation
      maintained at low level initiatively (INR:1.8-2.6), D-dimer testing were analyzed two times
      at 3 month later. In case of D-dimer level elevated, adjusted the intensity of
      anticoagulation to standard level. The endpoint of the study was the subsequent
      thromboembolic and major bleeding during an average follow-up of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Events;</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The bleeding events included cerebral hemorrhage, gastrointestinal bleeding and other major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. vision loss) or necessitates transfusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombotic Events</measure>
    <time_frame>24 months</time_frame>
    <description>The thrombotic events included valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism, and myocardial infarction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Deaths</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The deaths from all causes</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">772</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Standard intensity of anticoagulation</arm_group_label>
    <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low intensity and adjusted by elevated D-dimer</arm_group_label>
    <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low intensity without adjustment</arm_group_label>
    <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Standard intensity of anticoagulation</arm_group_label>
    <arm_group_label>Low intensity and adjusted by elevated D-dimer</arm_group_label>
    <arm_group_label>Low intensity without adjustment</arm_group_label>
    <other_name>Warfarin Sodium Tablets</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffered mechanical valves replacement because of valves dysfunction; and oral
        anticoagulation therapy with warfarin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age&gt;18years,male or female without pregnancy;

          2. Suffered the mechanical valves replacement in Wuhan Asia Heart Hospital;

          3. The operation type was Mitral valve replacement or Double valves replacement(aortic
             and mitral valve replacement).

        Exclusion Criteria: Patients with following diseases within 3 months.

          1. deep venous thromboembolism

          2. Pulmonary embolism

          3. Aortic dissection

          4. stroke

          5. Cerebral hemorrhage

          6. Myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhang zhenlu, PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhou xin, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>liu ze jin, PH.D</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WAHH</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <results_first_submitted>April 9, 2017</results_first_submitted>
  <results_first_submitted_qc>April 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2017</results_first_posted>
  <last_update_submitted>April 9, 2017</last_update_submitted>
  <last_update_submitted_qc>April 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mechanical valves replacement</keyword>
  <keyword>INR</keyword>
  <keyword>D-dimer</keyword>
  <keyword>thromboembolic events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Intensity of Anticoagulation</title>
          <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
        </group>
        <group group_id="P2">
          <title>Low Intensity and Adjusted by Elevated D-dimer</title>
          <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
        </group>
        <group group_id="P3">
          <title>Low Intensity Without Adjustment</title>
          <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="239"/>
                <participants group_id="P3" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Intensity of Anticoagulation</title>
          <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
        </group>
        <group group_id="B2">
          <title>Low Intensity and Adjusted by Elevated D-dimer</title>
          <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
        </group>
        <group group_id="B3">
          <title>Low Intensity Without Adjustment</title>
          <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="237"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="11.5"/>
                    <measurement group_id="B2" value="50.4" spread="11.9"/>
                    <measurement group_id="B3" value="50.1" spread="10.9"/>
                    <measurement group_id="B4" value="49.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elevated D-dimer(n)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Events;</title>
        <description>The bleeding events included cerebral hemorrhage, gastrointestinal bleeding and other major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. vision loss) or necessitates transfusion.</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intensity of Anticoagulation</title>
            <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity and Adjusted by Elevated D-dimer</title>
            <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity Without Adjustment</title>
            <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Events;</title>
          <description>The bleeding events included cerebral hemorrhage, gastrointestinal bleeding and other major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. vision loss) or necessitates transfusion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thrombotic Events</title>
        <description>The thrombotic events included valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism, and myocardial infarction.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intensity of Anticoagulation</title>
            <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity and Adjusted by Elevated D-dimer</title>
            <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity Without Adjustment</title>
            <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombotic Events</title>
          <description>The thrombotic events included valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism, and myocardial infarction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Deaths</title>
        <description>The deaths from all causes</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Intensity of Anticoagulation</title>
            <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity and Adjusted by Elevated D-dimer</title>
            <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity Without Adjustment</title>
            <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Deaths</title>
          <description>The deaths from all causes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Intensity of Anticoagulation</title>
          <description>After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
Warfarin</description>
        </group>
        <group group_id="E2">
          <title>D-dimer-guided Adjustmentd of Anticoagutlation Intensity</title>
          <description>The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
Warfarin</description>
        </group>
        <group group_id="E3">
          <title>Low Intensity Without Adjustment</title>
          <description>The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
Warfarin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombotic envents</sub_title>
                <description>including valve thrombosis, transient ischemic attack, ischemic stroke, peripheral embolism, and myocardial infarction.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>bleeding events</sub_title>
                <description>including cerebral hemorrhage, gastrointestinal bleeding and other major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. vision loss) or necessitates transfusion.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Deaths from other causes</sub_title>
                <description>Death from Heart failure,Cancer or unexplained death</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Litao Zhang</name_or_title>
      <organization>Wuhan Asia Heart Hospital</organization>
      <phone>+862765796888 ext 8204</phone>
      <email>zhengleetau@qq.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

